ResMed Reports Strong Q3 Earnings Amid Strategic Acquisition
ResMed Inc's stock fell 3.86% and hit a 20-day low amid broader market gains, with the Nasdaq-100 up 0.21% and the S&P 500 up 0.36%.
The company reported strong Q3 FY 2026 earnings, with revenue of $1.43 billion, an 11% year-over-year growth, and a strategic acquisition of Noctrix for $340 million expected to close soon. Despite rising component costs, ResMed anticipates maintaining gross margins between 62% and 63% for FY 2026, reflecting confidence in profitability and plans for share repurchases.
This strong financial performance, despite the stock's decline, indicates that investor sentiment may be influenced by the acquisition and future growth prospects, although the market's overall strength contrasts with the stock's movement.
Trade with 70% Backtested Accuracy
Analyst Views on RMD
About RMD
About the author

- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
- New Officer Appointment: A new officer has been appointed to a significant position within the organization.
- Responsibilities and Goals: The new officer is expected to bring fresh perspectives and drive initiatives aligned with the organization's objectives.
- Impact on the Team: This appointment is anticipated to enhance team dynamics and improve overall performance.
- Future Developments: The organization looks forward to the contributions of the new officer in upcoming projects and strategies.
- Hudson Technologies Decline: Hudson Technologies has a net cash position of $34.17 million, representing 12.9% of its market cap, yet its sales have declined by an average of 7.6% annually over the past two years, indicating adverse market trends, while its earnings per share have fallen by 39.1% annually, suggesting deteriorating profitability.
- ResMed's Sustained Growth: ResMed boasts a net cash position of $817.3 million, or 2.6% of its market cap, with constant currency growth averaging 9.1% over the past two years, demonstrating its ability to expand globally, and its earnings per share have increased by 15.2% annually, indicating strong profitability.
- Texas Pacific Land's Asset Strength: Texas Pacific Land holds a net cash position of $127 million, accounting for 0.4% of its market cap, with annual revenue growth of 26.2% over the last decade, reflecting increased market share, and a gross margin of 95% highlights its superior unit economics.
- Investment Flexibility: All three companies possess strong cash flows, with Hudson Technologies facing challenges, while ResMed and Texas Pacific Land show promising growth potential, allowing them to leverage their cash flows for investments or share buybacks.
- S&P 500 Strong Performance: The S&P 500 index rose by 0.29%, reaching an all-time high, driven by Apple's forecast of stronger-than-expected Q2 revenue, which boosted market sentiment and indicated increased investor confidence in tech stocks.
- Atlassian Stock Surge: Atlassian's stock soared over 29% after reporting Q3 revenue of $1.79 billion, exceeding the market expectation of $1.69 billion, highlighting a robust recovery in the software sector that may attract more investor interest.
- Oil Price Volatility Impacting Markets: WTI crude oil prices fell more than 3%, easing inflation concerns, although trade tensions resurfaced with President Trump's threat to raise tariffs on EU auto imports, potentially negatively affecting market sentiment.
- Economic Data Influencing Stocks: The April ISM manufacturing index remained unchanged at 52.7, below the expected 53.2, indicating signs of economic slowdown, despite the majority of companies reporting Q1 earnings that exceeded expectations, leaving the overall market facing uncertainty.
- Apple's Strong Earnings: Apple Inc. (AAPL) reported Q2 revenue of $111.18 billion, exceeding the consensus of $109.66 billion, and forecasted Q3 revenue growth of 14% to 17%, significantly above the expected 9.1%, which propelled the Dow Jones Industrial Average up over 4%.
- Software Stocks Surge: Atlassian (TEAM) posted Q3 revenue of $1.79 billion, surpassing the consensus of $1.69 billion, leading to a stock price increase of over 20%, which not only boosted the software sector but also enhanced investor confidence in tech stocks.
- Oil Price Volatility: WTI crude oil prices fell more than 3% due to developments in the US-Iran agreement, temporarily easing inflation concerns and contributing to stock market gains, highlighting the energy market's influence on the overall economy.
- Weak Manufacturing Data: The April ISM manufacturing index remained unchanged at 52.7, below the expected 53.2, while the prices paid sub-index rose to a four-year high of 84.6, indicating increasing price pressures that could impact Federal Reserve policy decisions.











